Enablex (darifenacin) and Ditropan XL (oxybutynin extended-release) are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Both therapies are antimuscarinic
The results, which were presented at Digestive Disease Week, show that, after up to 96 weeks of treatment, 94% of nucleoside-naive HBeAg-negative chronic hepatitis B patients treated with
The results come from a study investigating the cost-effectiveness of treating US patients who have mild chronic hepatitis C (CHC) using Pegasys (peginterferon alpha- 2a) plus Copegus (ribavirin).
Importantly, the study also demonstrated improvement in patient functioning, as measured by the personal and social performance scale (PSP) across a wide range of doses. This is the
The collaboration is intended to capitalize on Xoma's comprehensive antibody discovery, development and production technologies and expertise. Under the agreement, Schering-Plough will make up-front and milestone payments to
The specialty pharmaceutical firm has successfully completed a pharmacokinetics and scintigraphy study with fluticasone propionate, a commonly prescribed inhaled steroid treatment for asthma, in combination with Ventaira's next-generation
New data from several ongoing respiratory disease programs including pandemic flu, asthma, chronic obstructive pulmonary disorder (COPD), and idiopathic pulmonary fibrosis (IPF) were presented at the American Thoracic
Named PROTECT, the Peg-intron (peginterferon alfa-2b) plus Rebetol (ribavirin, USP) trial is targeted to enroll 125 hepatitis C virus (HCV) patients at approximately 28 liver transplant centers across
ZK-EPO is a novel epothilone that was strategically designed to overcome the limitations associated with other microtubule stabilizing agents by combining high potency with a wide therapeutic window.
The research, which has been published in Clinical Cancer Research, was authored by Dr Brittney-Shea Herbert and colleagues at Indiana University Cancer Center, along with Geron scientists. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.